Free Trial
NYSE:NUVB

Nuvation Bio Q3 2023 Earnings Report

Nuvation Bio logo
$2.46 +0.19 (+8.37%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$2.48 +0.02 (+0.61%)
As of 05/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvation Bio EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Nuvation Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvation Bio Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 2, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

Nuvation Bio's Q1 2025 earnings is scheduled for Wednesday, May 7, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nuvation Bio Earnings Headlines

Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Nuvation Bio initiated with an Outperform at Citizens JMP
See More Nuvation Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email.

About Nuvation Bio

Nuvation Bio (NYSE:NUVB), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

View Nuvation Bio Profile

More Earnings Resources from MarketBeat